Lung Cancer | Specialty

Study Confirms Prevalence of Low Testosterone Levels in Crizotinib-Treated Patients With NSCLC

May 23rd 2013

A new study has confirmed that low testosterone is a side effect in a large proportion of patients who received crizotinib for the treatment of ALK-positive non–small cell lung cancer.

LUX Program Examines Pan-HER Inhibitor Afatinib in Multiple Tumor Types

May 17th 2013

Researchers are attempting to determine if targeting more than one tyrosine kinase provide a greater benefit in several clinical trials involving the investigational drug afatinib.

High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer

May 15th 2013

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

In Treating Locally Advanced NSCLC, More Radiotherapy Is Not Better

May 15th 2013

Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.

Early Results Robust for New PD-L1 Immunotherapy Agent

May 15th 2013

An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.

FDA Approves Frontline Erlotinib With Novel Companion Diagnostic for Advanced NSCLC

May 14th 2013

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

Dr. Camidge on Targeted Therapies in Adjuvant NSCLC

May 7th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

Serendipity in Science: NSCLC Specialist Matches Therapies With Targets

May 3rd 2013

An interview with Alice Tsang Shaw, MD, PhD, who has won broad recognition for her contributions to the treatment of NSCLC, including the use of crizotinib to target the ROS1 gene rearrangement and research into other emerging agents.

What Is the Role of Maintenance Therapy in Cancer Care?

May 1st 2013

Experts provide an in-depth look at the treatment strategy in patients with solid tumors, specifically looking at the role of maintenance therapy.

Dr. Herbst on Selecting Patients for Molecular Testing

April 30th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.

Wide Variation Found in EGFR Testing Patterns

April 29th 2013

A study of patients newly initiated to erlotinib therapy for NSCLC found that there is no uniformity in the billing codes used for pharmacogenomic testing prior to starting the drug, making it difficult to analyze treatment patterns and cost impact.

USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical Practice

April 29th 2013

Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.

Novel Compound LDK378 Receives Breakthrough Designation for ALK+ NSCLC

March 15th 2013

The compound LDK378, a highly selective inhibitor of ALK, has been granted "Breakthrough Therapy Designation" by the FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer.

EGFR's Evolution: New Insights Refine Role of Mutation in NSCLC

March 1st 2013

Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.

EGFR Mutation Not a Prognostic Factor for NSCLC

February 28th 2013

Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.

Lung Cancer Risk Prediction Model

February 25th 2013

Using different selection criteria for screening is superior to currently recommended criteria.

The Cost-Effectiveness of Targeted Therapies in NSCLC

February 13th 2013

Impact of EGFR Mutations on Treatment Decisions in NSCLC

February 13th 2013

Access to Molecular Testing Therapy in NSCLC

February 13th 2013

Personalizing the Treatment of Lung Cancer

February 13th 2013